Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Will Maddox discuss a new Fierce special report identifying five cities with the potential to become major forces in the global biotech industry. Did your favorite city make the cut? Listen to find out. 

To learn more about the topics in this episode: 

• Top emerging biotech hubs in 2026 

• As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ 

• British biotech VC funding shows ‘signs of recovery,’ but IPO rebound yet to materialize 

• Could Basel be the next Boston? How the Swiss biotech hub is quietly raising its game 

This week's episode is sponsored by IQVIA Biotech.

 
Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

See omnystudio.com/listener for privacy information.